Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > New Filing today

<< Previous

Bullboard Posts

Next >>

Comment by palinc2000on Nov 07, 2023 10:20am

106 Views

Post# 35721364

RE:RE:RE:RE:RE:RE:RE:RE:RE:New Filing today

Ir was said that they altready know that they wont be able to meet the Adjusted Ebitda requirement and I am responding to that.
As far as this could be a posdibility sometimes in the future .... of course it could

SPCEO1 wrote: If you read what was said you will see nothing like THTX already being in default was stated. But they have been a serial defaulter already so one should consider all possibilities even if they seem unlikely at the moment.
palinc2000 wrote:
So you think that there is a chance that they would be already in default on an amendment signed on October 13 2023?
Please stop this collective schizophrenia..

JayjayUSA12007 wrote: "I would like to suggest that you send them a letter outlining the question and what the solution to this possibility is? We can't just leave it to somebody on the forum and you are the best person to ask this question and get clarification."

I agree. Having cash after this secondary would not satisfy the EBITDA requirement. They need to provide shareholders with an approach to avoid breaching Marathon demand.
With these incompetent and unethical people, anything is possible...